Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $261.00 | Outperform | Leerink Partners |
1/3/2024 | $242.00 | Overweight | Barclays |
12/14/2023 | $213.00 | Equal Weight | Wells Fargo |
12/14/2021 | $162.00 → $170.00 | Buy → Neutral | Citigroup |
11/26/2021 | $136.00 → $170.00 | Sector Perform | RBC Capital |
11/16/2021 | Underweight → Equal-Weight | Barclays | |
11/16/2021 | $158.00 → $170.00 | Outperform → Neutral | Credit Suisse |
11/16/2021 | Outperform → Market Perform | Raymond James |
Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items desc
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00
Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $242.00
Wells Fargo initiated coverage of Cencora with a rating of Equal Weight and set a new price target of $213.00
Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Frank Clyburn as a new independent director, effective October 1, 2024. With the election of Mr. Clyburn, the Board of Directors will increase to thirteen members. "Cencora's Board of Directors is pleased to welcome Mr. Clyburn as a director. His many years of executive experience, including within the pharmaceutical industry, will be an asset to the company as we continue to focus on long-term, sustainable growth," said Mark Durcan, Lead Independent Director. "Frank is a tenured executive leader who will bring valuable insights and perspectives to his role as a member of our Board," said Steven H. Collis,
Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improvin
Transaction Highlights Walgreens Boots Alliance announces sale of all remaining unencumbered shares of Cencora, Inc. for proceeds of approximately $1.1 billion $818 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora of $250 million Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSE:COR) common stock pursuant to Rule 144 for proceeds of $818 million and, subject to the completio
4 - Cencora, Inc. (0001140859) (Issuer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
SC 13D/A - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
SC 13G - CoreSite Realty Corp (0001490892) (Subject)
The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.25%. Currently, Cencora has a market capitalization of $44.28 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $264.37 today based on a price of $224.84 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:COR) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:MCK), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 6.78% on an annualized basis producing an average annual return of 19.86%. Currently, Cencora has a market capitalization of $43.81 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $247.56 today based on a price of $222.47 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)